Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proteinuria and cardiovascular disease.

W Weinstock Brown1, W F Keane

  • 1Department of Internal Medicine, Division of Nephrology, St. Louis Veterans Administration Medical Center, St. Louis, MO, USA. Wendy.brown@med.va.gov

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|September 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).

Journal of the renin-angiotensin-aldosterone system : JRAAS·2002
Same author

Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure.

Kidney international·2001
Same author

Metabolic pathogenesis of cardiorenal disease.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2001
Same author

The urgent call of albuminuria/proteinuria. Heeding its significance in early detection of kidney disease.

Postgraduate medicine·2001
Same author

[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].

Ugeskrift for laeger·2001
Same author

The national epidemic of chronic kidney disease. What we know and what we can do.

Postgraduate medicine·2001

Microalbuminuria and proteinuria are key indicators of kidney disease progression in diabetic and hypertensive patients. Early detection and intervention, including ACE inhibitors, can help slow kidney failure and reduce cardiovascular risks.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • Microalbuminuria/proteinuria is an established independent risk factor for renal disease progression in diabetes and hypertension.
  • Recent evidence highlights proteinuria as an independent risk factor for cardiovascular morbidity and mortality, even without overt kidney disease.

Purpose of the Study:

  • To summarize the established role of proteinuria in renal disease and its emerging significance in cardiovascular health.
  • To underscore the implications of proteinuria as a risk marker for cardiovascular disease.

Main Methods:

  • Review of clinical and experimental data on proteinuria.
  • Analysis of findings from clinical trials on angiotensin-converting enzyme inhibitors.
  • Synthesis of recent evidence linking proteinuria to cardiovascular outcomes.

Related Experiment Videos

Main Results:

  • Proteinuria predicts renal disease progression and cardiovascular events.
  • Angiotensin-converting enzyme inhibitors can slow renal disease progression, independent of blood pressure control.
  • Proteinuria is associated with a cluster of cardiovascular risk factors, including insulin resistance, hypertension, and dyslipidemia.

Conclusions:

  • Proteinuria is a critical marker for both kidney and cardiovascular disease.
  • Therapeutic interventions targeting proteinuria may delay kidney failure.
  • Identifying and managing proteinuria is crucial for cardiovascular risk stratification and treatment.